Shilanski & Associates, Inc. Bicycle Therapeutics PLC Transaction History
Shilanski & Associates, Inc.
- $289 Million
- Q1 2024
Shares
3 transactions
Others Institutions Holding BCYC
# of Institutions
99Shares Held
30.6MCall Options Held
85.5KPut Options Held
11.6K-
Baker Bros. Advisors LP New York, NY4.94MShares$99.9 Million1.56% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.49MShares$70.5 Million2.87% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY3.25MShares$65.6 Million3.03% of portfolio
-
Armistice Capital, LLC New York, NY1.67MShares$33.8 Million0.57% of portfolio
-
Tybourne Capital Management (Hk) LTD Hong Kong, K31.55MShares$31.2 Million8.61% of portfolio
About BICYCLE THERAPEUTICS plc
- Ticker BCYC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,676,100
- Market Cap $600M
- Description
- Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...